| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DYRK1B |
| Uniprot No | Q9Y463 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-629aa |
| 氨基酸序列 | MAVPPGHGPFSGFPGPQEHTQVLPDVRLLPRRLPLAFRDATSAPLRKLSVDLIKTYKHINEVYYAKKKRRAQQAPPQDSSNKKEKKVLNHGYDDDNHDYIVRSGERWLERYEIDSLIGKGSFGQVVKAYDHQTQELVAIKIIKNKKAFLNQAQIELRLLELMNQHDTEMKYYIVHLKRHFMFRNHLCLVFELLSYNLYDLLRNTHFRGVSLNLTRKLAQQLCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGTPYDLAIDMWSLGCILVEMHTGEPLFSGSNEVDQMNRIVEVLGIPPAAMLDQAPKARKYFERLPGGGWTLRRTKELRKDYQGPGTRRLQEVLGVQTGGPGGRRAGEPGHSPADYLRFQDLVLRMLEYEPAARISPLGALQHGFFRRTADEATNTGPAGSSASTSPAPLDTCPSSSTASSISSSGGSSGSSSDNRTYRYSNRYCGGPGPPITDCEMNSPQVPPSQPLRPWAGGDVPHKTHQAPASASSLPGTGAQLPPQPRYLGRPPSPTSPPPPELMDVSLVGGPADCSPPHPAPAPQHPAASALRTRMTGGRPPLPPPDDPATLGPHLGLRGVPQSTAASS |
| 分子量 | 95.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于重组人DYRK1B蛋白的参考文献及其简要摘要：
1. **"DYRK1B promotes cell proliferation and metastasis in hepatocellular carcinoma through regulating the cell cycle"**
- **作者**: Chen et al.
- **摘要**: 研究通过重组人DYRK1B蛋白实验，揭示其通过磷酸化周期蛋白依赖性激酶抑制因子(如p27)，促进肝癌细胞增殖和转移的机制。
2. **"Structural and functional characterization of human DYRK1B kinase domain"**
- **作者**: Johnson & Patel
- **摘要**: 利用重组表达的人DYRK1B激酶结构域进行晶体结构解析，分析其催化活性及底物结合特性，为靶向抑制剂设计提供基础。
3. **"DYRK1B regulates glucose homeostasis by modulating insulin signaling pathways"**
- **作者**: Gupta et al.
- **摘要**: 通过体外重组DYRK1B蛋白实验，发现其与胰岛素受体底物(IRS)的相互作用，影响葡萄糖代谢和胰岛素敏感性，提示其在糖尿病中的潜在作用。
4. **"Development of a high-throughput assay for DYRK1B inhibitors using recombinant protein"**
- **作者**: Lee et al.
- **摘要**: 报道了一种基于重组DYRK1B蛋白的激酶活性检测方法，用于筛选小分子抑制剂，评估其抗肿瘤药物的开发潜力。
(注：上述文献为示例，实际引用请查询具体数据库如PubMed或Web of Science获取真实文献。)
Recombinant human DYRK1B (dual-specificity tyrosine-regulated kinase 1B) is a engineered protein produced via genetic modification for research and therapeutic applications. DYRK1B belongs to the CMGC kinase family and plays critical roles in cell cycle regulation, differentiation, and survival. It phosphorylates substrates involved in signaling pathways such as the Hedgehog, Wnt, and insulin/IGF-1 cascades, impacting metabolic homeostasis and cancer progression. Notably, DYRK1B is overexpressed in certain cancers (e.g., pancreatic, ovarian) and metabolic disorders, where it promotes cell proliferation, chemoresistance, and insulin resistance.
The recombinant form, typically expressed in systems like *E. coli* or mammalian cells, retains the kinase activity and structural features (e.g., a conserved N-terminal kinase domain) of the native protein. It enables *in vitro* studies to dissect its molecular interactions, screen inhibitory compounds, or map post-translational modifications. Structural insights from crystallography or cryo-EM of recombinant DYRK1B aid in designing targeted therapies. Its role in metabolic diseases and cancer also positions it as a biomarker or therapeutic candidate, driving interest in modulating its activity to treat conditions like diabetes or chemotherapy-resistant tumors.
×
